394 related articles for article (PubMed ID: 20800630)
1. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35.
Sakurai F; Nakashima K; Yamaguchi T; Ichinose T; Kawabata K; Hayakawa T; Mizuguchi H
J Control Release; 2010 Dec; 148(2):212-8. PubMed ID: 20800630
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice.
Sakurai F; Kawabata K; Koizumi N; Inoue N; Okabe M; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2006 Jul; 13(14):1118-26. PubMed ID: 16541121
[TBL] [Abstract][Full Text] [Related]
3. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector.
Sakurai F; Mizuguchi H; Hayakawa T
Gene Ther; 2003 Jun; 10(12):1041-8. PubMed ID: 12776162
[TBL] [Abstract][Full Text] [Related]
4. Efficient gene delivery in human and rodent mast cells using adenovirus vectors.
Nakashima K; Sakurai F; Kawabata K; Mizuguchi H
J Control Release; 2008 Aug; 129(3):215-22. PubMed ID: 18572269
[TBL] [Abstract][Full Text] [Related]
5. Enhanced transduction efficiency of fiber-substituted adenovirus vectors by the incorporation of RGD peptides in two distinct regions of the adenovirus serotype 35 fiber knob.
Matsui H; Sakurai F; Katayama K; Kurachi S; Tashiro K; Sugio K; Kawabata K; Mizuguchi H
Virus Res; 2011 Jan; 155(1):48-54. PubMed ID: 20801174
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates.
Sakurai F; Nakamura SI; Akitomo K; Shibata H; Terao K; Kawabata K; Hayakawa T; Mizuguchi H
Gene Ther; 2009 Feb; 16(2):297-302. PubMed ID: 18800152
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of human CD46 by adenovirus serotype 35 vectors.
Sakurai F; Akitomo K; Kawabata K; Hayakawa T; Mizuguchi H
Gene Ther; 2007 Jun; 14(11):912-9. PubMed ID: 17377598
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.
Ni S; Gaggar A; Di Paolo N; Li ZY; Liu Y; Strauss R; Sova P; Morihara J; Feng Q; Kiviat N; Touré P; Sow PS; Lieber A
Cancer Gene Ther; 2006 Dec; 13(12):1072-81. PubMed ID: 16874361
[TBL] [Abstract][Full Text] [Related]
9. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
[TBL] [Abstract][Full Text] [Related]
10. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination.
DiPaolo N; Ni S; Gaggar A; Strauss R; Tuve S; Li ZY; Stone D; Shayakhmetov D; Kiviat N; Touré P; Sow S; Horvat B; Lieber A
Mol Ther; 2006 Apr; 13(4):756-65. PubMed ID: 16461009
[TBL] [Abstract][Full Text] [Related]
12. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
13. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.
Ophorst OJ; Kostense S; Goudsmit J; De Swart RL; Verhaagh S; Zakhartchouk A; Van Meijer M; Sprangers M; Van Amerongen G; Yüksel S; Osterhaus AD; Havenga MJ
Vaccine; 2004 Aug; 22(23-24):3035-44. PubMed ID: 15297053
[TBL] [Abstract][Full Text] [Related]
14. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates.
Sakurai F; Nakamura S; Akitomo K; Shibata H; Terao K; Kawabata K; Hayakawa T; Mizuguchi H
Mol Ther; 2008 Apr; 16(4):726-33. PubMed ID: 18362928
[TBL] [Abstract][Full Text] [Related]
15. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.
Muruve DA; Cotter MJ; Zaiss AK; White LR; Liu Q; Chan T; Clark SA; Ross PJ; Meulenbroek RA; Maelandsmo GM; Parks RJ
J Virol; 2004 Jun; 78(11):5966-72. PubMed ID: 15140994
[TBL] [Abstract][Full Text] [Related]
16. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.
Slager EH; van der Minne CE; Goudsmit J; van Oers JM; Kostense S; Havenga MJ; Osanto S; Griffioen M
Cancer Gene Ther; 2004 Mar; 11(3):227-36. PubMed ID: 14726960
[TBL] [Abstract][Full Text] [Related]
17. Suppressive effects of sugar-modified cationic liposome/NF-kappaB decoy complexes on adenovirus vector-induced innate immune responses.
Huang H; Sakurai F; Higuchi Y; Kawakami S; Hashida M; Kawabata K; Mizuguchi H
J Control Release; 2009 Jan; 133(2):139-45. PubMed ID: 18977256
[TBL] [Abstract][Full Text] [Related]
18. [Characterization of adenovirus serotype 35 vectors using genetically modified animals and non-human primates].
Sakurai F; Kawabata K; Mizuguchi H
Yakugaku Zasshi; 2006 Nov; 126(11):1013-9. PubMed ID: 17077607
[TBL] [Abstract][Full Text] [Related]
19. The short consensus repeats 1 and 2, not the cytoplasmic domain, of human CD46 are crucial for infection of subgroup B adenovirus serotype 35.
Sakurai F; Murakami S; Kawabata K; Okada N; Yamamoto A; Seya T; Hayakawa T; Mizuguchi H
J Control Release; 2006 Jul; 113(3):271-8. PubMed ID: 16790289
[TBL] [Abstract][Full Text] [Related]
20. Fiber-substituted conditionally replicating adenovirus for oncolysis of human renal carcinoma cells.
Nagaya H; Tagawa M; Hiwasa K; Terao S; Kanno T; Nishizaki T; Gotoh A
Anticancer Res; 2012 Jul; 32(7):2985-9. PubMed ID: 22753762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
